A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve ...

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian ...

Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these ...

Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Experts discuss lessons learned from implementing lipoprotein(a) (Lp[a]) testing in health care systems, how health systems can prioritize patients for testing based on the National Lipid ...

Panelists discuss how immunoglobulin A (IgA) nephropathy progression creates escalating economic burdens for patients through direct health care costs, lost productivity, increasing medication needs, ...

Panelists discuss how treatment success in immunoglobulin A (IgA) nephropathy extends beyond clinical trial end points to encompass sustained proteinuria reduction, stable kidney function, symptom ...

As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through ...

Drug companies and specialty distributors navigate challenges like profitability, supply chain volatility, regulatory complexities, and market pressures to build successful partnerships, said Natalie ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...